NCT02036645View on ClinicalTrials.gov

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

February 4, 2014

Primary Completion Date

September 15, 2016

Study Completion Date

September 15, 2016

Conditions
Mild-Moderate Alzheimer's DiseaseHealthy Elderly
Interventions
BIOLOGICAL

MEDI1814 for IV injection

Monoclonal antibody for IV Injection

BIOLOGICAL

MEDI1814 for Subcutaneous Injection

Monoclonal antibody for subcutaneous injection

BIOLOGICAL

IV Placebo

Placebo for IV injection

BIOLOGICAL

Placebo for Subcutaneous Injection

Subcutaneous Placebo Injection

Trial Locations (10)

21225

Research Site, Baltimore

32806

Research Site, Orlando

33009

Research Site, Hallandale

33012

Research Site, Hialeah

33165

Research Site, Miami

73112

Research Site, Oklahoma City

84106

Research Site, Salt Lake City

90806

Research Site, Long Beach

91206

Research Site, Glendale

91402

Research Site, Panorama City

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY